ReviewComplementary therapies in medicine2025
From farm to bedside: Potential of medical cannabis in global health.
Review in Complementary therapies in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
27 authors.
Funding
Abstract
introductionThe growing opioid crisis and persistent global health disparities underscore the urgent need for alternative therapeutic strategies. Cannabis, with its long-standing historical use and recent legislative developments, presents a potentially significant avenue for addressing these challenges. This review examines the evolving landscape of medicinal cannabis, drawing from historical ethnopharmacological data and contemporary scientific discussions.
methodsThis review synthesized evidence from historical ethnobotanical records, peer-reviewed studies, and outcomes derived from recent Global Health events. These events facilitated discussions among diverse stakeholders, including healthcare professionals, policymakers, researchers, industry representatives, farmers, and patient advocates. Case studies and successful models from the USA and Africa, including the recent FDA approval for first-in-human clinical trials of a medicinal cannabis derivative for pancreatic cancer, were analysed.
resultsSuccessful models include collaborative platforms fostering stakeholder engagement, such as partnerships between African farmers and biotech firms to standardize cultivation. Successful models demonstrate the potential for adaptation and scaling in diverse healthcare settings. The FDA trial approval exemplifies progress in clinical translation. However, disparities persist, with patients within Africa facing systemic barriers to medical Cannabis certification and higher rates of punitive opioid discontinuation.
conclusionMedicinal Cannabis presents a complex yet promising solution for reducing opioid-related mortality and addressing healthcare inequities. Implementing strategic frameworks like CORE (Care, Outreach, Research, Education) is essential for developing safe, high-quality, evidence-based cannabis products. Through fostering collaboration and addressing existing obstacles, the therapeutic potential of medicinal Cannabis can be harnessed to mitigate the opioid crisis and reduce global health disparities, effectively translating research from farm to bedside.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.